# Impact of Symbiofilm On Nasal Microbiota

> **NCT05015530** · — · COMPLETED · sponsor: **Lallemand Pharma AG** · enrollment: 12 (actual)

## Conditions studied

- Rhinosinusitis Chronic
- Microbiome

## Interventions

- **DEVICE:** Healsea® Chronic, hypertonic seawater-based nasal spray supplemented with natural Symbiofilm® extract

## Key facts

- **NCT ID:** NCT05015530
- **Lead sponsor:** Lallemand Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-12
- **Primary completion:** 2023-05-19
- **Final completion:** 2023-05-19
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05015530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05015530, "Impact of Symbiofilm On Nasal Microbiota". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05015530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*